Brain Cancer | Clinical

December 06, 2021

ST101, an agent being investigated in a phase 1/2 clinical trial, has been granted fast track designation from the FDA for the treatment of patients with glioblastoma multiforme.

November 10, 2021

Arturo Loaiza-Bonilla, MD, MSEd, FACP, discussed recent trials and advances in neuroendocrine cancer research in an interview with Targeted Oncology for World Neuroendocrine Cancer Day.

November 10, 2021

From precision radiotherapeutics to small molecule inhibitors, Scott Paulson, MD, discusses a new array of pharmacological treatments for World Neuroendocrine Cancer Day.

November 05, 2021

The phase 3 COMPOSE trial is the second trial to look at 177Lu-edotreotide in somatostatin receptor-positive disease.

October 11, 2021

The designation is based on a phase 1/2 study of the agent in patients 3-19 years of age.

October 08, 2021

Alpha DaRT, an intraumoral conformal alpha-irradiation strategy, has been granted a second breakthrough device designation by the FDA.

September 23, 2021

Compared with historic controls, the use of adjuvant VAL-083 after chemoradiotherapy and temozolomide may improve outcomes for select patients with glioblastoma multiforme.

September 17, 2021

During the past 4 decades, glioblastoma has remained a cancer with one of the worst prognoses and is among the most debilitating.

August 31, 2021

LP-184 is moving forward in the course of development and was granted an orphan drug designation by the FDA.

August 31, 2021

For patients with neuroendocrine tumors, the chances of dying of cancer were higher than dying of other causes, but mortality largely varies by primary tumor site.